<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="et al DemmingerDaniel E1WalzLisa2DietertKristina3HoffmannHelen4PlanzOliver4GruberAchim D3von MesslingVeronika2WolffThorstenhttps://orcid.org/0000-0001-7688-236X1WolffT@rki.de[1], Unit 17—Influenza and Other" exact="Respiratory" post="VirusesRobert Koch Institute BerlinGermany[2], Veterinary Medicine DivisionPaul�?Ehrlich�?Institute LangenGermany[3], Department"/>
 <result pre="of antibodies targeting the head and stalk regions of the" exact="viral" post="protein HA, and activating FcγR�?dependent responses. adeno�?associated virus vector"/>
 <result pre="Current seasonal influenza vaccines show low effectiveness and protection is" exact="limited" post="to the virus strains contained within the vaccine. High"/>
 <result pre="vaccine. Introduction Influenza remains a severe public health threat. The" exact="infection" post="is associated with high morbidity and mortality, especially in"/>
 <result pre="Influenza viruses are genetically and antigenically highly variable, resulting in" exact="recurrent" post="epidemics in humans (&quot;flu season�?). The main mechanism driving"/>
 <result pre="from the porcine reservoir and imposed a high burden of" exact="disease" post="on public health (Fineberg, 2014). Currently, the most effective"/>
 <result pre="influenza vaccine (LAIV) is available for children, its usefulness is" exact="limited" post="in adults due to pre�?existing immunity against previously encountered"/>
 <result pre="e.g., H5N1 or H7N9, which can be associated with increased" exact="disease" post="severity (WHO, 2018a). Hence, there is a generally accepted"/>
 <result pre="al, 1982). Since these epitopes are highly variable, antibodies show" exact="limited" post="cross�?protection (Yu et al, 2008). Significantly, broadly protective antibodies"/>
 <result pre="their protective effect via interference with later steps in the" exact="viral" post="replicative cycle or via Fc�?receptor (FcR)�?mediated mechanisms, including antibody�?dependent"/>
 <result pre="al, 2013). However, pre�?existing ADCC�?activating antibody titers induced following natural" exact="infection" post="could be boosted in humans by inactivated vaccine, indicating"/>
 <result pre="&amp;amp; Tompkins, 2014). Also, AAV vectors are re�?administrable into the" exact="respiratory" post="tract in the context of pre�?existing immunity without need"/>
 <result pre="ferrets via expression of broadly reactive HA�?stalk antibodies in the" exact="respiratory" post="tract (Balazs et al, 2013; Limberis et al, 2013a,b;"/>
 <result pre="and surface (HA) influenza virus antigens protected mice from challenge" exact="infection" post="(Xin et al, 2001; Lin et al, 2009; Sipo"/>
 <result pre="Lin et al, 2009; Sipo et al, 2011). In the" exact="absence of" post="neutralizing antibodies against heterologous HA, the protection against a"/>
 <result pre="the ferret model, thought to most accurately represent human influenza" exact="disease" post="(Enkirch &amp;amp; von Messling, 2015). A detailed knowledge of"/>
 <result pre="used herein was isolated from human tissue and efficiently transduces" exact="respiratory" post="tissue of mice and ferrets (Gao et al, 2004;"/>
 <result pre="al, 2011). All vector stocks contained high amounts of encapsidated" exact="viral" post="genomes (vg) and relatively low amounts of empty capsids"/>
 <result pre="(Fig EV1A). Furthermore, AAV9�?vector�?neutralizing antibodies were induced, which correlated with" exact="total" post="anti�?AAV9 serum IgG titers (Fig EV1B and C). Figure"/>
 <result pre="Cal/7/9 WIV per 50 μl was given i.n. two times." exact="Blood" post="samples were taken at indicated time points (red drops)."/>
 <result pre="antibody responses against the AAV vector capsid and PR8�?specific IgA" exact="Total" post="IgG ELISA titer induction over vaccination period against AAV9�?vector"/>
 <result pre="a dilution of 1:100. Mean ± SD. Regression analysis of" exact="total" post="AAV9�?vector IgG ELISA titers and MN50 titers. Coefficient of"/>
 <result pre="MN50 titers. Coefficient of correlation (r2) and P�?value are shown." exact="Total" post="IgG ELISA titers expressed as AUC against homologous Cal/7/9"/>
 <result pre="covering several subtypes of group 1 and 2, though at" exact="lower" post="intensities (Fig 2G). IgA antibodies confer protection to respiratory"/>
 <result pre="at lower intensities (Fig 2G). IgA antibodies confer protection to" exact="respiratory" post="pathogens due to their high local abundance in the"/>
 <result pre="pathogens due to their high local abundance in the airway" exact="mucosa" post="(Asahi et al, 2002). We determined pre�?challenge levels of"/>
 <result pre="to the RBS, can also inhibit later steps in the" exact="viral" post="replication cycle as well (Brandenburg et al, 2013). To"/>
 <result pre="RBS, at the lateral site of the head and/or the" exact="upper" post="part of the stalk region, as well as at"/>
 <result pre="vaccination with AAV�?vectored vaccines or WIV APhylogenetic tree of the" exact="complete" post="HA sequences of the four H1N1 viruses used for"/>
 <result pre="incubated with serum before binding was detected with a HRP�?coupled" exact="secondary" post="antibody. Data are shown as fold induction over AAV�?GFP"/>
 <result pre="undergoes major conformational changes, which eventually results in fusion of" exact="viral" post="and endosomal membranes and release of the viral genome"/>
 <result pre="fusion of viral and endosomal membranes and release of the" exact="viral" post="genome into the cytoplasm. HA�?stalk binding antibodies may interfere"/>
 <result pre="with these steps and thus execute an inhibitory effect on" exact="viral" post="replication (Ekiert et al, 2011). However, antibodies preventing HA"/>
 <result pre="antibodies against a heterologous virus strain, i.e., PR8, although at" exact="lower" post="levels (Fig 4B). Notably, AAV�?HA, AAV�?cHA, and WIV total"/>
 <result pre="at lower levels (Fig 4B). Notably, AAV�?HA, AAV�?cHA, and WIV" exact="total" post="PR8 antibody titers were not predictive for FcγR antibody"/>
 <result pre="the FcγR assay and correlation between PR8 FcγR titer and" exact="total" post="IgG ELISA titer AScheme of FcγR assay setups used"/>
 <result pre="FcγR assay setups used to detect FcγR�?activating antibodies against all" exact="viral" post="proteins. MDCKII cells were either infected with influenza virus"/>
 <result pre="FcγR�?reporter cell, which is quantified by anti�?IL�?2 ELISA. BCorrelation between" exact="total" post="influenza IgG ELISA titers and FcγR�?activating antibody titers against"/>
 <result pre="FcγR assay setups used to detect FcγR�?activating antibodies against the" exact="complete" post="HA protein (C) or the HA�?stalk domain (D). Uninfected"/>
 <result pre="we assessed serum antibodies with transfected target cells expressing either" exact="complete" post="HA or a stalk�?only HA (Fig EV3C and D)."/>
 <result pre="EV3C and D). In fact, the signal observed with the" exact="complete" post="HA was much more pronounced in comparison with HA�?stalk�?only"/>
 <result pre="animals of the negative control group (AAV�?GFP) succumbed to the" exact="infection" post="(Fig 5A). AAV�?cHA and WIV protected four out of"/>
 <result pre="points) or day 14 post�?infection (black points) (D) with the" exact="lower" post="dose of PR8 9 (n = 6 mice per"/>
 <result pre="animals were finally able to clear the virus, despite the" exact="absence of" post="pre�?existing neutralizing antibodies against PR8 (Fig EV4D, Table 1)."/>
 <result pre="mice immunized with AAV�?HA or AAV�?cHA were protected from severe" exact="disease" post="and death (71%; 5/7), which was also reflected by"/>
 <result pre="superior to two doses of WIV in reducing mortality and" exact="disease" post="severity against heterologous influenza challenge in mice. AAV�?vectored vaccines"/>
 <result pre="severity against heterologous influenza challenge in mice. AAV�?vectored vaccines reduce" exact="disease" post="severity in ferrets The protective efficacy of AAV�?vectored vaccines"/>
 <result pre="multiple comparison testing (*P &amp;lt; 0.05, **P &amp;lt; 0.01). The" exact="lower" post="table indicates Cal/7/9�?specific MN50 and HAI mean titers. Assays"/>
 <result pre="histological sections of bronchi (I) and lung parenchyma with alveolar" exact="epithelial" post="cells (AEC, J). Arrowheads: areas of suppurative bronchitis/bronchiolitis; arrows:"/>
 <result pre="Degree of bronchiolitis, necrosis of submucosal glands (SMG). and alveolar" exact="epithelial" post="cells (AEC) were examined by board�?certified pathologists. Data information:"/>
 <result pre="of the early (H1N1)pdm isolate A/Mexico/InDRE4487/2009, which can cause severe" exact="disease" post="in ferrets (Meunier et al, 2012). During the 3�?day"/>
 <result pre="examination (Fig 6A). All animals developed classical signs of influenza" exact="disease" post="starting on day 1, including serous nasal exudate, congestion,"/>
 <result pre="classical signs of influenza disease starting on day 1, including" exact="serous" post="nasal exudate, congestion, frequent sneezing, wheezing, and depression (Fig"/>
 <result pre="1, including serous nasal exudate, congestion, frequent sneezing, wheezing, and" exact="depression" post="(Fig 6C). However, ferrets receiving AAV�?HA or AAV�?cHA recovered"/>
 <result pre="by a return to normal activity levels and improvement of" exact="respiratory" post="signs compared to QIV and AAV�?GFP�?immunized groups. Moreover, for"/>
 <result pre="in QIV�?immunized animals until day 3 post�?infection, while only a" exact="short" post="fever peak was seen in the AAV vector vaccinated"/>
 <result pre="other groups (3–6%; Fig 6E). Virus was isolated from the" exact="respiratory" post="tract of all animals to various extents, indicating that"/>
 <result pre="Furthermore, neutralizing antibody titers in AAV�?HA�?immunized animals correlated with reduced" exact="viral" post="titers in the nasal turbinates (Fig EV5E). Immunohistochemical staining"/>
 <result pre="only rare virus antigen in the submucosal glands and bronchial" exact="epithelial" post="cells when compared to the AAV�?cHA�? or AAV�?GFP�?immunized ferrets,"/>
 <result pre="These results indicate that AAV�?HA and AAV�?cHA immunization reduced the" exact="disease" post="severity after homologous influenza virus infection in ferrets. However,"/>
 <result pre="and AAV�?cHA immunization reduced the disease severity after homologous influenza" exact="virus infection" post="in ferrets. However, only with AAV�?HA this was also"/>
 <result pre="AAV�?cHA immunization reduced the disease severity after homologous influenza virus" exact="infection" post="in ferrets. However, only with AAV�?HA this was also"/>
 <result pre="it has been appreciated that innovative delivery platforms such as" exact="viral" post="vectors could be an important element on the quest"/>
 <result pre="(Erbelding et al, 2018; Ortiz et al, 2018). Commonly used" exact="viral" post="vectors have proven their efficacy as influenza vaccine carriers"/>
 <result pre="(de Vries &amp;amp; Rimmelzwaan, 2016). However, most &quot;traditional�? vectors express" exact="viral" post="gene products and/or induce strong inflammatory responses, causing safety"/>
 <result pre="inflammatory responses, causing safety concerns. Reports regarding genotoxicity have been" exact="limited" post="to wild�?type AAV infection (Nault et al, 2015), while"/>
 <result pre="concerns. Reports regarding genotoxicity have been limited to wild�?type AAV" exact="infection" post="(Nault et al, 2015), while AAV vectors show an"/>
 <result pre="were successfully used in preclinical active immunization studies against several" exact="infectious diseases" post="(Nieto &amp;amp; Salvetti, 2014). Furthermore, AAV vectors can be"/>
 <result pre="might also be explored as useful carriers for other conserved" exact="viral" post="antigens such as NA or M2e (Krammer et al,"/>
 <result pre="the exact mechanism remains unclear, since these antibodies target a" exact="viral" post="antigen supposedly localized in the interior of the virion"/>
 <result pre="remains unclear, since these antibodies target a viral antigen supposedly" exact="localized" post="in the interior of the virion or host cell"/>
 <result pre="immunization with AAV�?HA or AAV�?cHA confers protection against a homologous" exact="viral" post="challenge. However, only AAV�?HA�?immunized ferrets showed reduced virus replication"/>
 <result pre="cHA expressed by influenza B�?, VSV�?, or AdV vectors reduced" exact="viral" post="titers (Krammer et al, 2014). Unexpectedly, AAV�?GFP�?immunized ferrets, though"/>
 <result pre="allowing for more efficient replication and severe damage of the" exact="upper" post="respiratory tract compared to the other groups, which might"/>
 <result pre="for more efficient replication and severe damage of the upper" exact="respiratory" post="tract compared to the other groups, which might have"/>
 <result pre="low (Boutin et al, 2010), suggesting an advantage over other" exact="viral" post="vectors in the context of pre�?existing immunity which critically"/>
 <result pre="this finding included most likely continuous generation of antigen by" exact="respiratory" post="cells after mucosal immunization, and the lung�?specific environment, which"/>
 <result pre="to mammalian gene expression and de novo synthesized (GeneArt®, Thermo" exact="Fisher" post="Scientific, Regensburg, Germany). The construction of AAV�?HA and AV�?NP"/>
 <result pre="of the head regions, i.e., regions cysteine52–cysteine277, derived from of" exact="avian influenza" post="A viruses of the subtypes H2, H10, or H13"/>
 <result pre="High quantity and quality of AAV9�?vector stocks were verified by" exact="infectious" post="titer determination, electron microscopy, ELISA, and TaqMan qPCR (forward"/>
 <result pre="of RKI's unit 17 and tested negative for mycoplasma contamination." exact="Infections" post="with influenza viruses were performed in cell culture medium"/>
 <result pre="content was determined via BCA (Thermo Fischer Scientific, Hennigsdorf, Germany)." exact="Infectious" post="titers were determined by plaque assay on MDCKII cells."/>
 <result pre="β�?propiolactone, and purified by ultracentrifugation through a 20% sucrose cushion." exact="Protein" post="content was determined by Lowry assay. A sample was"/>
 <result pre="A sample was deglycosylated and separated on reducing SDS–PAGE, and" exact="viral" post="protein content was determined with Coomassie staining. Antigenicity of"/>
 <result pre="AAV vector plasmids for 24 h using Lipofectamine 2000 (Thermo" exact="Fisher" post="Scientific) according to the manufacturer's instruction. Cells were fixed,"/>
 <result pre="Biological Inc., Eching, Germany), or animal serum followed by suitable" exact="secondary" post="antibody coupled to AlexaFluor488 (1:1,000; Thermo Fisher Scientific). Nuclei"/>
 <result pre="followed by suitable secondary antibody coupled to AlexaFluor488 (1:1,000; Thermo" exact="Fisher" post="Scientific). Nuclei were stained with DAPI. Cells were analyzed"/>
 <result pre="AAV vector plasmids for 48 h using Lipofectamine 2000 (Thermo" exact="Fisher" post="Scientific) according to the manufacturer's instruction. Alternatively, 293T cells"/>
 <result pre="performed by incubation with anti�?V5�?tag (1:1,000; SV5�?Pk1) antibody and suited" exact="secondary" post="antibody coupled to horseradish peroxidase (HRP) (1:10,000; Agilent Technologies,"/>
 <result pre="was performed by incubation with mouse serum (1:500) and suited" exact="secondary" post="antibody coupled to HRP (1:10,000; Agilent Technologies). Blots were"/>
 <result pre="of SuperSignal™ West Dura Extended Duration Substrate (Thermo Fischer Scientific)." exact="Mouse" post="serum and lung homogenate ELISA For serum ELISA, MaxiSorb™"/>
 <result pre="or with pcHA3 for 48 h using Lipofectamine 2000 (Thermo" exact="Fisher" post="Scientific). Cells were fixed, permeabilized, blocked, and incubated with"/>
 <result pre="monolayer assay Immunoperoxidase monolayer assay (IPMA) was used to determine" exact="total" post="antibody titers in ferret sera against Cal/7/9 virus and"/>
 <result pre="MDCKII cells were infected with Cal/7/9 at a multiplicity of" exact="infection" post="of 0.01 and incubated at 37°C for 2 days."/>
 <result pre="with anti�?influenza A polyclonal antibody (1:1,000; 5315�?0064; Bio�?Rad) and suited" exact="secondary" post="antibody coupled to HRP (1:1,000; Agilent Technologies). AAV MN"/>
 <result pre="or pAAV�?mHL1 plasmids for 24 h using Lipofectamine 2000 (Thermo" exact="Fisher" post="Scientific). 50 μl of twofold serial serum dilutions in"/>
 <result pre="approval F107/117 and IMI17 by Regierungspräsidium Tübingen). Handling of mice" exact="Female" post="6�? to 8�?week�?old C57BL/6 mice were purchased from Charles"/>
 <result pre="of ketamine (100 mg/kg) and medetomidine (0.05 mg/kg), before a" exact="total" post="of 300 μl PBS containing 7.5 × 1012 vg"/>
 <result pre="(Influsplit Tetra®, GSK, Brenford, USA) was given intramuscularly into the" exact="posterior" post="limbs two times in parallel with the first and"/>
 <result pre="parallel with the first and the second AAV vector vaccine." exact="Blood" post="samples were collected before each and after the last"/>
 <result pre="200 μl Opti�?MEM. Ferrets were monitored daily for signs of" exact="disease" post="using a 0�?1�?2 scale for each activity (normal, calm,"/>
 <result pre="using a 0�?1�?2 scale for each activity (normal, calm, depressed)," exact="respiratory" post="signs (sneezing, nose exudate, and congestion), and general clinical"/>
 <result pre="2018). Final clinical scores were calculated by summation of activity," exact="respiratory" post="signs, and general clinical sign records per ferret per"/>
 <result pre="lesions using lung�?specific inflammation score parameters for quantifying influenza virus�?induced" exact="pneumonia" post="as described (Dietert et al, 2017). These parameters included"/>
 <result pre="et al, 2017). These parameters included severity of (i) interstitial" exact="pneumonia" post="with infiltration by macrophages, lymphocytes, neutrophils (ii) bronchitis, (iii)"/>
 <result pre="pneumonia with infiltration by macrophages, lymphocytes, neutrophils (ii) bronchitis, (iii)" exact="epithelial" post="necrosis of bronchi, alveoli, and submucosal glands, (iv) perivascular"/>
 <result pre="alveoli, and submucosal glands, (iv) perivascular lymphocytic cuffing, and (v)" exact="hyperplasia" post="of type II pneumocytes. For immunohistochemical detection of influenza"/>
 <result pre="submucosal glands, (iv) perivascular lymphocytic cuffing, and (v) hyperplasia of" exact="type II" post="pneumocytes. For immunohistochemical detection of influenza A virus, heat�?mediated"/>
 <result pre="differences between survival curves were calculated with log�?rank (Mantel–Cox) test." exact="Linear" post="regression analysis was performed with default settings in GraphPad."/>
 <result pre="CD4 T cell help is limiting and selective during the" exact="primary" post="B cell response to influenza virus infection. J Virol88:"/>
 <result pre="and selective during the primary B cell response to influenza" exact="virus infection." post="J Virol88: 314–32424155379 AltmanMO, BenninkJR, YewdellJW, HerrinBR (2015) Lamprey"/>
 <result pre="SatoY, ShimadaS, NannoM, MatsuokaY, OhwakiMet al (2002) Protection against influenza" exact="virus infection" post="in polymeric Ig receptor knockout mice immunized intranasally with"/>
 <result pre="ShimadaS, NannoM, MatsuokaY, OhwakiMet al (2002) Protection against influenza virus" exact="infection" post="in polymeric Ig receptor knockout mice immunized intranasally with"/>
 <result pre="BalazsAB, BloomJD, HongCM, RaoDS, BaltimoreD (2013) Broad protection against influenza" exact="infection" post="by vectored immunoprophylaxis in mice. Nat Biotechnol31: 647–65223728362 BangaruS,"/>
 <result pre="Spectrum of pathogen�? and model�?specific histopathologies in mouse models of" exact="acute" post="pneumonia. PLoS One12: e018825129155867 DiLilloDJ, TanGS, PaleseP, RavetchJV (2014)"/>
 <result pre="TempertonNet al (2018) Cross�?protective immune responses induced by sequential influenza" exact="virus infection" post="and by sequential vaccination with inactivated influenza vaccines. Front"/>
 <result pre="al (2018) Cross�?protective immune responses induced by sequential influenza virus" exact="infection" post="and by sequential vaccination with inactivated influenza vaccines. Front"/>
 <result pre="Sci USA111: 13133–1313825157133 EnkirchT, von MesslingV (2015) Ferret models of" exact="viral" post="pathogenesis. Virology479–480: 259–270 ErbeldingEJ, PostDJ, StemmyEJ, RobertsPC, AugustineAD, FergusonS,"/>
 <result pre="influenza vaccine: the strategic plan for the national institute of" exact="allergy" post="and infectious diseases. J Infect Dis218: 347–35429506129 collab: FDA"/>
 <result pre="the strategic plan for the national institute of allergy and" exact="infectious diseases." post="J Infect Dis218: 347–35429506129 collab: FDA (2018) Approved products"/>
 <result pre="MullarkeyCE, HamiltonJR, WongCK, LeonPE, UccelliniMB, ChromikovaV, HenryC, HoffmanKWet al (2017)" exact="Alveolar" post="macrophages are critical for broadly�?reactive antibody�?mediated protection against influenza"/>
 <result pre="ZipsM�?L, CroweBA, KreilTR, EhrlichHJet al (2011) Vectors based on modified" exact="vaccinia" post="ankara expressing influenza H5N1 hemagglutinin induce substantial cross�?clade protective"/>
 <result pre="ZhuXY, HoffmanRMB, van MeersbergenR, HuizinghJ, WanningenP, VerspuijJet al (2015) A" exact="stable" post="trimeric influenza hemagglutinin stem as a broadly protective immunogen."/>
 <result pre="KrammerF (2017) Strategies to induce broadly protective antibody responses to" exact="viral" post="glycoproteins. Expert Rev Vaccines16: 503–51328277797 KrammerF, FouchierRAM, EichelbergerMC, WebbyRJ,"/>
 <result pre="TangC, van DiepenH, ObmolovaGet al (2018) Universal protection against influenza" exact="infection" post="by a multidomain antibody to influenza hemagglutinin. Science (New"/>
 <result pre="of the broadly neutralizing antibody FI6 in mouse airway provides" exact="partial" post="protection against a new avian influenza A virus, H7N9."/>
 <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9. Clin Vaccine Immunol20: 1836–183724132603 LinJ, CalcedoR,"/>
 <result pre="universal influenza virus vaccine candidate confers protection against pandemic H1N1" exact="infection" post="in preclinical ferret studies. NPJ Vaccines2: 2629263881 NassSA, MattinglyMA,"/>
 <result pre="ImbeaudS, FranconiA, MalletM, CouchyG, LetouzeE, PilatiC, VerretB, BlancJFet al (2015)" exact="Recurrent" post="AAV2�?related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet47:"/>
 <result pre="Nat Genet47: 1187–119326301494 NietoK, SalvettiA (2014) AAV vectors vaccines against" exact="infectious diseases." post="Front Immunol5: 524478774 OkunoY, IsegawaY, SasaoF, UedaS (1993) A"/>
 <result pre="RyderAB, NachbagauerR, BuonocoreL, PaleseP, KrammerF, RoseJK (2015) Vaccination with vesicular" exact="stomatitis" post="virus�?vectored chimeric hemagglutinins protects mice against divergent influenza virus"/>
 <result pre="and redundant roles of activating FcgammaRs in protection against influenza" exact="disease" post="by M2e�?specific IgG1 and IgG2a antibodies. J Virol129: 850–862"/>
 <result pre="internal influenza virus proteins. EBioMedicine8: 277–29027428437 de VriesRD, RimmelzwaanGF (2016)" exact="Viral" post="vector�?based influenza vaccines. Hum Vaccin Immunother12: 2881–290127455345 WalzL, KaysSK,"/>
 <result pre="collab: WHO (2018a) Cumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018 In Cumulative number of"/>
 <result pre="WHO, 2003–2018 In Cumulative number of confirmed human cases for" exact="avian influenza." post="Geneva, Switzerland: World Health Organizationhttps://www.who.int/influenza/human_animal_interface/2018_03_02_tableH5N1.pdf collab: WHO (2018b) Influenza"/>
 <result pre="virus vaccine induces a long�?term humoral immune response to human" exact="immunodeficiency" post="virus. Hum Gene Ther12: 1047–106111399227 YassineHM, BoyingtonJC, McTamneyPM, WeiCJ,"/>
</results>
